MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.860 +0.180 (+3.85%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 ↗
Coya Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics ↗
100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha 
Via Talk Markets
News headline image
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
7 Biotech Stocks to Put on Your Breakthrough Radar ↗
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
News headline image
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases ↗
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,... 
Via Benzinga
News headline image
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024 ↗
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in BTIG Fireside Discussion
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases ↗
Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story